# US 2014/0154245 A1 · Humanized anti-emap ii antibody and use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0154245 A1 - Document ID: US20140154245A1 - Status: Published application - Kind: A1 - Application number: 14/113,209 - Filed: 2011-07-14 - Published: 2014-06-05 - Earliest claimed: 2011-04-20 - Assignees: Hee Koung Kim; L&K Biomed Co., Ltd.; Cell & Bio Co., Ltd. - Inventors: Kang-Jun Yoon - Web page: https://patentgrep.com/patent/US20140154245A1 ## CPC - C07K 16/24: against cytokines, lymphokines or interferons - C07K 16/18: against material from animals or humans - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The present invention provides a humanized anti-EMAP II antibody, the use of the humanized antibody, and pharmaceutical compositions containing the humanized antibody. The humanized anti-EMAP II antibody shows reduced immunogenicity and increased half-life while having similar or improved antigen binding capacity compared to the parent monoclonal antibody. Thus, the humanized anti-EMAP II antibody of the present invention can be more effectively used as a diagnostic reagent for EMAP II and a therapeutic agent for diseases that are mediated by EMAP II. ## Claims ### Claim 1 A humanized anti-EMAPII (endothelial monocyte activating polypeptide II) antibody, comprising: (i) a light-chain variable domain having an amino acid sequence set forth in any one of SEQ ID NO: 12 to SEQ ID NO: 18; and (ii) a heavy-chain variable domain having an amino acid sequence set forth in any one of SEQ ID NO: 20 to SEQ ID NO: 26. ### Claim 2 (depends on 1) The humanized anti-EMAPII antibody of claim 1, wherein the humanized anti-EMAPII antibody comprises a pair of a light-chain variable domain and a heavy-chain variable domain selected from the group consisting of a light-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 12, and a heavy-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 20; a light-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 13, and a heavy-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 21; a light-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 14, and a heavy-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 22; a light-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 15, and a heavy-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 23; a light-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 16, and a heavy-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 24; a light-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 17, and a heavy-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 25; and a light-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 18, and a heavy-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 26. ### Claim 3 (depends on 1) The humanized anti-EMAPII antibody of claim 1, wherein the humanized anti-EMAPII antibody further comprises a constant domain derived from human IgG 1. ### Claim 4 (depends on 1) A pharmaceutical composition for preventing or treating a TNF-α-mediated disease or Alzheimer's disease, comprising a humanized anti-EMAPII antibody of claim 1. ### Claim 5 (depends on 4) The pharmaceutical composition of claim 4, wherein the TNF-α-mediated disease is selected from the group consisting of adult respiratory distress syndrome; anorexia; cancer; chronic fatigue syndrome; graft versus host rejection; hyperalgesia; inflammatory bowel disease; neuroinflammatory diseases; ischemic/reperfusion injury, including cerebral ischemia; brain injury as a result of trauma, epilepsy, hemorrhage or stroke; diabetes; multiple sclerosis; ocular diseases; pain; pancreatitis; pulmonary fibrosis; rheumatoid arthritis, osteoarthritis, juvenile (rheumatoid) arthritis, seronegative polyarthritis, ankylosing spondylitis, Reiter's syndrome and reactive arthritis, psoriatic arthritis, enteropathic arthritis, polymyositis, dermatomyositis, scleroderma, systemic sclerosis, vasculitis, cerebral vasculitis, Sjögren's syndrome, rheumatic fever, polychondritis and polymyalgia rheumatica and giant cell arteritis; septic shock; side effects from radiation therapy; systemic lupus erythematous; temporal mandibular joint disease; and thyroiditis. ### Claim 6 (depends on 1) A kit for quantification of EMAPII, comprising a humanized anti-EMAPII antibody of claim 1. ### Claim 7 A nucleic acid molecule encoding a light-chain variable domain having an amino acid sequence set forth in any one of SEQ ID NO: 12 to SEQ ID NO: 18. ### Claim 8 A nucleic acid molecule encoding a heavy-chain variable domain having an amino acid sequence set forth in any one of SEQ ID NO: 20 to SEQ ID NO: 26. ### Claim 9 A recombinant vector, comprising nucleic acid molecules encoding a light-chain variable domain having an amino acid sequence set forth in any one of SEQ ID NO: 12 to SEQ ID NO: 18 and/or heavy-chain variable domain having an amino acid sequence set forth in any one of SEQ ID NO: 20 to SEQ ID NO: 26. ### Claim 10 (depends on 9) A transformed cell, comprising the recombinant vector of claim 9. ### Claim 11 (depends on 10) A method of producing a humanized anti-EMAPII antibody, comprising culturing the transformed cell of claim 10. ### Claim 12 (depends on 1) A method of preventing or treating a TNF-α-mediated disease or Alzheimer's disease, comprising administering a humanized anti-EMAPII antibody of claim 1. ### Claim 13 A chimeric anti-EMAPII antibody, comprising: a light-chain variable domain having an amino acid sequence set forth in SEQ ID NO: 11; and a heavy-chain variable domain set forth in SEQ ID NO: 19. ### Claim 14 (depends on 2) A pharmaceutical composition for preventing or treating a TNF-α-mediated disease or Alzheimer's disease, comprising a humanized anti-EMAPII antibody of claim 2. ### Claim 15 (depends on 3) A pharmaceutical composition for preventing or treating a TNF-α-mediated disease or Alzheimer's disease, comprising a humanized anti-EMAPII antibody of claim 3. ### Claim 16 (depends on 2) A method of preventing or treating a TNF-α-mediated disease or Alzheimer's disease, comprising administering a humanized anti-EMAPII antibody of claim 2. ### Claim 17 (depends on 3) A method of preventing or treating a TNF-α-mediated disease or Alzheimer's disease, comprising administering a humanized anti-EMAPII antibody of claim 3. ### Claim 18 (depends on 4) A method of preventing or treating a TNF-α-mediated disease or Alzheimer's disease, comprising administering a pharmaceutical composition of claim 4. ### Claim 19 (depends on 5) A method of preventing or treating a TNF-α-mediated disease or Alzheimer's disease, comprising administering a pharmaceutical composition of claim 5.